
Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Matthew Lunning, DO¹, Philip J. Bierman, MD¹, R. Gregory Bociek, MD¹, Rathy Cutter, RN, BSN², Emily K. Pauli, BMBS, PharmD², Peter Sportelli⁴, Hari P. Miskin, MS⁴, Michael S. Weiss⁴ and Julie M Vose, MD¹ ¹University of Nebraska Medical Center, Omaha, NE; ²Clearview Cancer Institute, Huntsville, AL; ³City of Hope National Medical Center, Duarte, CA; ⁴TG Therapeutics, Inc., New York, NY

Background

Ublituximab

- Ublituximab (TG-1101, UTX) is a novel, chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen, and glycoengineered to enhance affinity for all variants of FcyRIIIa receptors, thereby demonstrating greater antibody-dependent cellular cytotoxicity (ADCC) activity than rituximab and ofatumumab.
- Ublituximab is currently in Phase 3 development in combination with ibrutinib or TGR-1202 for patients with chronic lymphocytic leukemia (CLL), and in Phase 2b study for patients with Diffuse Large B-Cell Lymphoma (DLBCL).



Red: Amino acids contributing to ofatumumab Amino acids essential or rituximab. but not ofatumumab binding Purple: Core amino acids of ublituximab epitope

TGR-1202

- \bullet High selectivity to the δ isoform of PI3K
- once-daily dosing; and
- ΡΙ3Κδ other to hepatic toxicity observed to date

Fold-selectivity								
Isoform	ΡΙ3Κα ΡΙ3Κβ		ΡΙ3Κγ	ΡΙ3Κδ				
TGR-1202	>1000	>50	>48	1				
¹ Idelalisib	>300	>200	>40	1				
² IPI-145	>640	>34	>11	1				

Study Design


Study UTX-TGR-103 (NCT02006485) is a Ph I/Ib trial evaluating the combination of ublituximab + TGR-1202 in patients with relapsed or refractory NHL and CLL. Following safe evaluation of the UTX + TGR doublet, a triplet cohort was opened evaluating the combination of UTX + TGR + bendamustine restricted to enrollment for DLBCL and Follicular Lymphoma patients:

Dose Escalation Schema:

Ublituximab Dose	TGR Dose (QD)	Bendamustine
900 mg	600 mg	90 mg/m ²
900 mg	800 mg	90 mg/m ²

Treatment Schedule:

Efficacy is assessed at Week 8 and every 12 weeks thereafter. After Month 12, all patients remain on TGR-1202 single agent.





\Rightarrow TGR-1202 (TGR) is a next generation PI3K δ inhibitor, with a unique structure and activity profile distinct from other PI3Kδ inhibitors in development, including:

✤A prolonged half-life that enables

A differentiated safety profile from inhibitors development, notably with respect and colitis







¹Flinn et al. 2009, ²Porter et al. 2012

Study Objectives

Primary Objectives

To determine the Safety and Maximum Tolerated Dose (MTD) of UTX + TGR + Bendamustine

Secondary Objectives

To assess Efficacy (overall response) rate, time to response, duration of response, progression free survival)

Key Eligibility Criteria


- Confirmed diagnosis of Diffuse Large Follicular B-Cell (DLBCL) or Lymphoma (FL)
- Relapsed after, or refractory to, at least 1 prior treatment regimen with no limit on prior therapies
- **\therefore** ECOG performance status ≤ 2
- Adequate organ system function: ANC \geq 750/µL; platelets \geq 50 K/µL
- Patients relapsed or refractory to prior PI3KS inhibitors or prior BTK inhibitors are eligible.
- Patients relapsed from prior autologous stem cell transplant after 90 days are eligible


Results						
Demographics						
Evaluable for Safety (n)	19					
Evaluable for Efficacy ⁺ (n)	15					
Median Age, years (range)	68 (31 – 81)					
Male/Female	11/8					
Histology	DLBCL	11				
	FL	8				
ECOG, 0/1/2	3/15/1					
Prior Therapy Regimens, median (range)	2 (1 – 6)					
Patients with ≥ 3 Prior Therapies, n (%)	ents with ≥ 3 Prior Therapies, n (%) 7 (37					
Refractory to Prior Therapy, n (%)	9 (47%)					
Refractory to Rituximab, n (%)	11 (58%)					
[†] 4 Patients not evaluable (3 too early, 1 non-related AE prior to efficacy assessment)						

S	Safety											_
All Causality AE's Occurring in \geq 15% of Patients (n = 19)								Pts	CR	PR		
	Adverse Event	All Grades		Grade 3/4		DLBCL		(n) 7	(n) 3	(n) 2	n (%) 5 (71%)	(r 1
		Ν	%	Ν	%	FL		8	3	4	7 (88%)	-
	Diarrhea	7	37%	1	5%	Total		15	6	6	12 (80%)	1
	Decreased appetite	6	32%	1	5%							
	Nausea	6	32%	1	5%							
	Anemia	4	21%	2	11%	1%		GR - L/P (
	Neutropenia	4	21%	4	21%	Histology	Dose	Rel/Ref	f Prior Therapies			
	Vitamin D decreased	4	21%	-	-	DLBCL	600	Ref		R-C	HOP, R-ICE	
	Arthralgia	3	16%	_	-	DLBCL	600	Ref	Ref R-CHOP, R-ICE		-ICE, BEAM- <mark>ASC</mark>	Т
	Asthenia	3	16%	_	_	DLBCL	600	Rel			R-CHOP	
	Dysgeusia	3	16%	1	5%	DLBCL	800	Ref	Rof R-CH(OP, R-Adria,	
	Hypomagnesemia	3	16%	1	5%			500 Rel		Pembro + Acalabrutinib		
						DLBCL	600			R-CHOP		
	Infusion related reaction	3	16%	-	-	DLBCL	800	Ref	R-CHOP, R-Benda, ASCT, R-GEN			√/ОХ,
	Rash	3	16%	1	5%		000	Dal	П		Revlimid	` T
	Thrombocytopenia	3	16%	1	5%	DLBCL FL	800 600	Rel Rel	K.	•	-ICE, BEAM-ASC	1
						FL	600	Ref	D (POCH, ASCT	ah
	Mean time on study 6 cycles					FL	600	Rel	R-CHOP, Radiation, Rituximab			
	 No patient has discontinued due to a treatment-related AE Growth factor support was restricted during Cycle 1 for DLT 					FL	600	Rel	R-Benda, R + Idelalisib, CPI-1205			205
Growth factor support was restricted during Cycle 1 for DLT evaluation purposes					FL	800	Ref	R-Benda, Rituximab R-CHOP				
	No Grade 3/4 transaminase elevations have been reported											
1 transient event of Grade 3 diarrhea (duration of 1 day) was					FL	600	Rel	CHOP, R-ICE, ASCT				
reported					FL	600	Rel	R-CHOP				
No events of pneumonia or pneumonitis have been reported to					FL	600	Ref			R-CHOP		

- No events of pneumonia or pneumonitis have been reported to date

Efficacy





Presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, December 3 – 6, 2016, San Diego, CA

ectrum, Celgene. Siddigi: Seattle Genetics, Pharmacyclics/Janssen, Kite. Blumel: TG Therapeutics, Inc. (Consultancy) Sportelli: TG Therapeutics, Inc. (Employment, Equity Ownership). Miskin: TG Therapeutics, Inc. (Employment, Equity Ownership). Weiss: TG Therapeutics, Inc. (Employment, Equity Ownership)